All questionsPharmacology: Repatha (evolocumab), all indications6 questions · 2 sourcesMechanismWhat type of drug is Repatha?“REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor” (opens the source at this quote in a new tab)CopyFlag“Evolocumab is a human monoclonal immunoglobulin G2 (IgG2) directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). Evolocumab has an approximate molecular weight (MW) of 144 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.” (opens the source at this quote in a new tab)CopyFlagHow does Repatha work (mechanism of action)?“Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.” (opens the source at this quote in a new tab)CopyFlag“Normally, PCSK9 binds to the LDL receptor (LDLR) on the surface of hepatocytes, leading to the degradation of the LDLR and higher LDL-C levels. Repatha® enhances removal of LDL-cholesterol by inhibiting PCSK9, increasing the number of LDL receptors on the surface of the liver, resulting in reduction of LDL-C from circulation.” (opens the source at this quote in a new tab)CopyFlagHow quickly does Repatha lower LDL cholesterol?“Following single subcutaneous administration of 140 mg or 420 mg of evolocumab, maximum suppression of circulating unbound PCSK9 occurred by 4 hours. Unbound PCSK9 concentrations returned toward baseline when evolocumab concentrations decreased below the limit of quantitation. Maximum LDL-C reduction occurred by 2 weeks after a single-dose of 140 mg of evolocumab and by 3 weeks after a single-dose of 420 mg of evolocumab.” (opens the source at this quote in a new tab)CopyFlag“Assess LDL-C when clinically appropriate. The LDL-lowering effect of REPATHA may be measured as early as 4 weeks after initiation.” (opens the source at this quote in a new tab)CopyFlagPharmacokineticsWhat is the half-life of Repatha?“REPATHA was estimated to have an effective half-life of 11 to 17 days.” (opens the source at this quote in a new tab)CopyFlag“An approximate 2- to 3-fold accumulation was observed in trough serum concentrations (Cmin 7.21 µg/mL) following 140 mg doses administered subcutaneously every 2 weeks or following 420 mg doses administered subcutaneously monthly (Cmin 11.2 µg/mL), and serum trough concentrations approached steady-state by 12 weeks of dosing.” (opens the source at this quote in a new tab)CopyFlag“Following a single subcutaneous dose of 140 mg or 420 mg evolocumab administered to healthy adults, median peak serum concentrations were attained in 3 to 4 days, and estimated absolute bioavailability was 72%.” (opens the source at this quote in a new tab)CopyFlagHow is Repatha metabolized and eliminated?“Two elimination phases were observed for REPATHA. At low concentrations, the elimination is predominately through saturable binding to target (PCSK9), while at higher concentrations the elimination of REPATHA is largely through a non-saturable proteolytic pathway.” (opens the source at this quote in a new tab)CopyFlag“Since monoclonal antibodies are not known to be eliminated via renal pathways, renal function is not expected to impact the pharmacokinetics of evolocumab.” (opens the source at this quote in a new tab)CopyFlagComponentsWhat are the inactive ingredients in Repatha?“REPATHA is a sterile, preservative-free, clear to opalescent, colorless to pale yellow solution for subcutaneous use. Each 1 mL prefilled single-dose pen, prefilled single-dose SureClick® autoinjector and prefilled single-dose syringe contains 140 mg evolocumab, acetate (1.2 mg), polysorbate 80 (0.1 mg), proline (25 mg) in Water for Injection, USP. Sodium hydroxide may be used to adjust to a pH of 5.0.” (opens the source at this quote in a new tab)CopyFlag